95 CI Pack-years Smoked Before Age 30 Years 1 (n = 1,085,062 person-years) HR 95 CI 10 (n = 560,470 person-years) HR 95 CI Ptrendb Pheterogeneity c 20 (n = 744,382 person-years) HR 95 CI Age at Start off of Smoking, years 20 (n = 976,780 person-years) HR 95 CI Ptrendb Pheterogeneity contact colorectal cancer No. Age-adjusted Multivariated CIMP status CIMP-low/negative No. Age-adjusted Multivariated CIMP-high No. Age-adjusted Multivariated MSI status MSS No. Age-adjusted Multivariated MSI-high No. Age-adjusted Multivariated BRAF mutation status BRAF-wildtype No. Age-adjusted Multivariate No. Age-adjusted Multivariated d490 1.00 1.00 Referent Referent 1.09 1.414 0.96, 1.25 0.92, 1.20 1.31 1.300 1.14, 1.52 1.08, 1.45 0.0002 0.003 0.09 1.16 1.347 1.01, 1.33 0.97, 1.29 1.21 1.402 1.06, 1.38 1.01, 1.33 0.004 0.03 0.377 1.00 1.00 Referent Referent 71 1.00 1.00 Referent Referent 1.33 1.29 1.16 1.322 1.00, 1.35 0.96, 1.31 74 0.96, 1.85 0.93, 1.79 1.62 1.54 1.13 1.222 0.95, 1.34 0.90, 1.28 50 1.11, 2.35 1.06, two.25 0.01 0.02 0.05 1.27 1.23 0.09 0.30 1.19 1.274 1.01, 1.39 0.98, 1.35 57 0.89, 1.80 0.87, 1.75 1.50 1.44 1.16 1.301 0.99, 1.35 0.95, 1.30 71 1.08, two.09 1.03, 2.01 0.02 0.03 0.21 0.05 0.400 1.00 1.00 Referent Referent 63 1.00 1.00 Referent Referent 1.58 1.53 1.ten 1.323 0.95, 1.28 0.92, 1.24 75 1.12, two.21 1.09, 2.15 1.61 1.55 1.13 1.240 0.96, 1.33 0.91, 1.27 45 1.09, two.40 1.04, two.31 0.01 0.01 0.39 1.62 1.57 0.ten 0.32 1.11 1.275 0.95, 1.29 0.92, 1.26 63 1.14, 2.30 1.11, 2.24 1.45 1.39 1.15 1.318 0.99, 1.33 0.94, 1.28 60 1.01, 2.06 0.97, 1.99 0.03 0.06 0.73 0.07 0.Am J Epidemiol. 2013;178(1):84404 1.00 1.00 Referent Referent 67 1.00 1.00 Referent Referent 1.25 1.21 1.14 1.334 0.99, 1.32 0.95, 1.28 68 0.89, 1.75 0.86, 1.71 1.35 1.29 1.16 1.253 0.99, 1.37 0.94, 1.31 37 0.89, 2.04 0.85, 1.96 0.08 0.13 0.41 1.30 1.26 0.03 0.15 1.15 1.289 0.Moclobemide 99, 1.Tedizolid 34 0.96, 1.31 53 0.90, 1.86 0.88, 1.82 1.24 1.20 1.17 1.328 1.01, 1.36 0.PMID:23626759 97, 1.31 56 0.87, 1.78 0.83, 1.72 0.21 0.30 0.07 Table continues 0.03 0.BRAF-mutatedDNMT3B expression statusAm J Epidemiol. 2013;178(1):84Table 5. ContinuedNever Smoker (n = 1,383,154 person-years) HR 95 CI Pack-years Smoked Just before Age 30 Years 1 (n = 1,085,062 person-years) HR 95 CI 10 (n = 560,470 person-years) HR 95 CI Ptrendb Pheterogeneity c 20 (n = 744,382 person-years) HR 95 CI Age at Start out of Smoking, years 20 (n = 976,780 person-years) HR 95 CI Ptrendb Pheterogeneity cDNMT3B-negative No. Age-adjusted Multivariate No. Age-adjusted Multivariated d238 1.00 1.00 Referent Referent 52 1.00 1.00 Referent Referent 0.67 0.65 1.23 1.222 1.02, 1.48 0.99, 1.45 27 0.42, 1.08 0.41, 1.04 0.93 0.87 1.09 1.131 0.87, 1.35 0.83, 1.30 24 0.56, 1.53 0.53, 1.45 0.72 0.53 0.82 0.80 0.25 0.54 1.21 1.179 1.00, 1.48 0.97, 1.45 27 0.52, 1.32 0.50, 1.28 0.76 0.72 1.17 1.191 0.97, 1.42 0.92, 1.37 28 0.48, 1.21 0.45, 1.15 0.23 0.15 0.08 0.DNMT3B-positiveSmoking Cessation and Colorectal Cancer EpigeneticsAbbreviations: CI, confidence interval; CIMP, CpG island methylator phenotype; DNMT3B, DNA methyltransferase 3B; HR, hazard ratio; MSI, microsatellite instability; MSS, microsatellite steady. a All models had been stratified by calendar year in the questionnaire cycle, age, and sex. b Primarily based around the linear trend test by utilizing the median worth of every single category. c Tests for heterogeneity (for a multivariate HR linear trend) on the associations of smoking with one particular molecular subtype versus the other molecular subtype (i.e., CIMP-low/negative vs. CIMP-high; MSS.
